Iovance Biotherapeutics (NASDAQ: IOVA) shares jumped over 14% in premarket trading after the company significantly raised its full-year 2026 revenue outlook to $410M-$420M. This updated forecast, driven by strong adoption of its Amtagvi therapy, exceeds the prior guidance midpoint by $55M and clears consensus analyst estimates of $402.8M 🔗.
Key points:
- Guidance Increase: Midpoint of new guidance ($415M) is 3.0% above consensus.
- Commercial Momentum: Strong domestic adoption of Amtagvi and sustained Proleukin sales cited.
- Expansion: On track to expand authorized treatment centers to 110 by year-end 2026.
- Profitability: Operational efficiencies accelerating timeline toward profitability.
Iovance shares jump in premarket as raised outlook clears consensus views
STREETINSIDER.COMSep 29, 1:11 PM UTC
0